Takeda completes Shire acquisition
Takeda has completed its £46-billion acquisition of Shire, a deal that took just eight months to see through from announcement to close.
Read More
Tag: neuroscience
Pfizer unveils $600m investment in venture capital arm
Pfizer is planning to invest $600 million in biotechnology and other emerging growth companies through its venture investment group.
Read More
Novartis snaps up AveXis in $8.7bn deal
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.
Read More
Shire to split operations in two
Shire has unveiled plans to split its operations into two separate entities – a neuroscience division and rare diseases one, and will later decide whether they should be listed independently.
Read More
Pfizer pulls plug on early stage neuroscience projects
Pfizer has announced a planned cull of all early-stage projects in neuroscience and the related loss of around 300 jobs.
Read More
AZ links with Berg in AI-based drug discovery deal
AstraZeneca and US biopharma Berg have entered a research pact to identify and evaluate novel targets and therapeutics to treat neurological disorders with the help of artificial intelligence. AZ also announced expanded approval in the US of breast cancer drug Faslodex.
Read More
Shire mulls over separation of neuroscience unit
Shire is considering cleaving its neuroscience division into a separate, publicly-listed entity in a move that would afford the firm a sharper focus on rare diseases.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
